… and reduced ejection fraction (HFrEF). In this analysis of DAPA-HF, we describe the efficacy
of dapagliflozin on the predefined secondary end point of total failure hospitalizations (first …

… SGLT2 inhibitor dapagliflozin, compared with placebo, led to significant reductions in
cardiovascular death and heart failure hospitalization. We examined the effect of dapagliflozin on …

… concentration and submaximal exercise capacity in patients with heart failure and
preserved ejection fraction: the PARALLAX randomized clinical trial". JAMA . 2021;326:1919-1929. …

… Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.  … 2 inhibitor
dapagliflozin first apparent among patients with heart failure with mildly reduced or preserved …

… Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and
reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care. 2021;44:586-594. …

… outcome in clinical trials in patients with heart failure and reduced ejection fraction (HFrEF) is
… Dapagliflozin in patients with heart failure and reduced ejection fraction.N Engl J Med. 2019…

… hospitalization for heart failure in patients who have heart failure with preserved ejection
fraction (… This study sought to determine whether treatment with dapagliflozin affects pulmonary …

… patients with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy
and safety of dapagliflozin… SBP in Dapagliflozin and Prevention of Adverse Outcomes in Heart …

… with Preserved Ejection Fraction Heart Failure) trial, using previously validated actuarial …
use of dapagliflozin in patients with HF with mildly reduced or preserved ejection fraction overall …

… of dapagliflozin might apply to patients who have heart failure with preserved ejection
fraction or those who have heart failure with mildly reduced ejection fraction across glycaemia …